Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod Pretreatment for Intradermal Influenza Vaccine in Young Adults
NCT02103023Phase 3Completed
- Sponsor
- The University of Hong Kong
- Start
- Mar 2014
- Primary completion
- Nov 2014
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of imiquimod in influenza (4 arms), sponsored by The University of Hong Kong. Primary endpoint: Seroconversion rate at Day 7. Started Mar 2014; status: completed.
02
Drugs
imiquimod
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02103023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103023.